KLK2-comPAS / 78278343PCR3001
KLK2-comPAS / 78278343PCR3001: A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
Trial summary:
Receptor status / problem studied:
Inclusion criteria
Exclusion criteria
Open for recruitment
Trial Title
KLK2-comPAS / 78278343PCR3001
Diagnosis
Prostate cancer
Type of trial
Pharmaceutical
Type of treatement
Medical Oncology
Phase
III
Locations
Investigators
Principal Investigator